Anthera Pharmaceuticals
ANTH · OTC
$0.0001+$0.0001 (+0.00%)TodayMarket closed ·
No price history for this range.
EPS: actual vs estimate
Beat the estimate in 3 of the last 8 quarters, by 21.2% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q1 FY18 | -$0.561 | -$0.57 | −1.6% |
| Q4 FY17 | -$0.675 | -$0.73 | −8.1% |
| Q3 FY17 | -$0.9313 | -$0.58 | +37.7% |
| Q2 FY17 | -$1.11 | -$0.86 | +22.6% |
| Q1 FY17 | -$1.41 | -$1.57 | −11.0% |
| Q4 FY16 | -$3.31 | -$3.20 | +3.4% |
| Q3 FY16 | -$3.06 | -$4.88 | −59.5% |
| Q2 FY16 | -$2.50 | -$2.80 | −12.1% |
Earnings calls
- Special Call - Anthera Pharmaceuticals, Inc.
- Special Call - Anthera Pharmaceuticals, Inc.
- Special Call - Anthera Pharmaceuticals, Inc.
- Anthera Pharmaceuticals' (ANTH) Craig Thompson on Clinical Updates Call Transcript
- Earnings call Q1 2013
- Earnings call Q3 2012
- Special Call - Anthera Pharmaceuticals, Inc.
- Special Call - Anthera Pharmaceuticals, Inc.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.